Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+1,74%
1 094,84
+18,71
+1,74%
—1 076,131 079,891 100,771 079,89——
SIXC
Communications
SIXC
Communications
SIXC
-0,42%
604,21
-2,53
-0,42%
—606,74606,74607,90602,03——
SIXE
Energy
SIXE
Energy
SIXE
+0,07%
1 249,71
+0,89
+0,07%
—1 248,821 246,371 256,421 239,08——
SIXI
Industrials
SIXI
Industrials
SIXI
+0,86%
1 739,26
+14,90
+0,86%
—1 724,361 733,021 745,751 727,76——
SIXM
Financials
SIXM
Financials
SIXM
+0,01%
635,63
+0,040
+0,01%
—635,59635,08637,96633,31——
SIXR
Staples
SIXR
Staples
SIXR
+0,61%
848,32
+5,17
+0,61%
—843,15842,50852,77840,85——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,22%
216,76
+0,47
+0,22%
—216,29216,29217,30215,24——
SIXT
Technology
SIXT
Technology
SIXT
+2,20%
3 335,14
+71,73
+2,20%
—3 263,413 296,253 343,663 295,42——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,01%
939,34
+0,10
+0,01%
—939,24941,57948,11939,11——
SIXV
Health care
SIXV
Health care
SIXV
+0,38%
1 468,17
+5,61
+0,38%
—1 462,561 465,031 471,561 459,66——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,28%
2 387,09
+6,69
+0,28%
—2 380,402 394,922 412,132 386,82——
CVM:NYSEAMERICAN
CEL-SCI Corp
1,74 USD
+2,96%
(+0,050) 1D
1,75 USD
+0,57% (+0,0100)
After hours
Closed: 5-май, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CVM...
Open
1,70 USD
High
1,86 USD
Low
1,50 USD
Mkt. cap
14,72 млн
Avg. vol.
129,80 миң
Volume
0,00
52-wk high
13,48 USD
52-wk low
1,50 USD
EPS
-5,24 USD
Beta
0,70
Shares outstanding
8,46 млн
No. of employees
43
News stories
From sources across the web
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees43
Foundedмар. 1983
HeadquartersВьенна, Вирджиния, Америка Кошмо Штаттары
Sector-
Websitecel-sci.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
-
-
-
-
Cost of goods sold
4,01 млн
3,74 млн
3,70 млн
3,68 млн
Cost of revenue
4,01 млн
3,74 млн
3,70 млн
3,68 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,38 млн
1,75 млн
2,33 млн
1,69 млн
Operating expense
2,38 млн
1,75 млн
2,33 млн
1,69 млн
Total operating expenses
6,39 млн
5,49 млн
6,03 млн
5,37 млн
Operating income
-6,39 млн
-5,49 млн
-6,03 млн
-5,37 млн
Other non operating income
-
-3,77 миң
60,94 миң
-
EBT including unusual items
-6,57 млн
-5,66 млн
-6,10 млн
-5,47 млн
EBT excluding unusual items
-6,57 млн
-5,66 млн
-6,10 млн
-5,46 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-6,57 млн
-5,66 млн
-6,10 млн
-5,47 млн
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-178,29 миң
-172,05 миң
-128,50 миң
-87,79 миң
Net interest expenses
-178,29 миң
-172,05 миң
-128,50 миң
-87,79 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-5,42 млн
-4,53 млн
-5,51 млн
-4,40 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer